Skip to main content
Erschienen in: BMC Infectious Diseases 1/2016

Open Access 01.12.2016 | Case report

Non-nosocomial healthcare-associated left-sided Pseudomonas aeruginosa endocarditis: a case report and literature review

verfasst von: Hideharu Hagiya, Takeshi Tanaka, Kohei Takimoto, Hisao Yoshida, Norihisa Yamamoto, Yukihiro Akeda, Kazunori Tomono

Erschienen in: BMC Infectious Diseases | Ausgabe 1/2016

Abstract

Background

With the development of invasive medical procedures, an increasing number of healthcare-associated infective endocarditis cases have been reported. In particular, non-nosocomial healthcare-associated infective endocarditis in outpatients with recent medical intervention has been increasingly identified.

Case presentation

A 66-year-old man with diabetes mellitus and a recent history of intermittent urethral self-catheterization was admitted due to a high fever. Repeated blood cultures identified Pseudomonas aeruginosa, and transesophageal echocardiography uncovered a new-onset severe aortic regurgitation along with a vegetative valvular structure. The patient underwent emergency aortic valve replacement surgery and was successfully treated with 6 weeks of high-dose meropenem and tobramycin. Historically, most cases of P. aeruginosa endocarditis have occurred in the right side of the heart and in outpatients with a history of intravenous drug abuse. In the case presented, the repeated manipulations of the urethra may have triggered the infection. Our literature review for left-sided P. aeruginosa endocarditis showed that non-nosocomial infection accounted for nearly half of the cases and resulted in fatal outcomes as often as nosocomial cases. A combination therapy with anti-pseudomonal beta-lactams or carbapenems and aminoglycosides may be the preferable treatment. Medical treatment alone may be effective, and surgical treatment should be carefully considered.

Conclusions

We presented a rare case of native aortic valve endocarditis caused by P. aeruginosa. This case illustrates the importance of identifying the causative pathogen(s), especially for outpatients with a recent history of medical procedures.

Background

Infective endocarditis (IE) continues to be associated with high morbidity and mortality, even with advancements in medical care. Most cases of IE occur outside of the healthcare setting, but an increasing number of healthcare-associated IE (HCA-IE) are consistently being reported [1]. According to a recent prospective, multicenter, cohort study, 16 % of IE cases (127/793) were categorized as HCA-IE [2]. Further, a clinically important new type of IE, non-nosocomial healthcare-associated IE (NNHCA-IE), which is defined as IE cases originating from outpatients who underwent medical cares in community settings, has been identified in recent years [2]. These cases of NNHCA-IE account for between 9.3 and 15.7 % of all cases of IE [36].
Pseudomonas aeruginosa is typically associated with nosocomial infections. Whereas, the organism is historically known to cause community-acquired IE, which develops primarily in the right side of the heart of patients with a history of intravenous drug (IVD) abuse [7, 8]. Due to an increase in invasive medical interventions, cases of P. aeruginosa-induced HCA-IE have also recently increased [9]. However, the incidence of P. aeruginosa endocarditis is still significantly low compared to the incidence of endocarditis due to other pathogens [10], and the clinical characteristics of the infection are not well known. Herein, we report a case of left-sided NNHCA-IE caused by P. aeruginosa, along with a review of the recent literature.

Case presentation

A 66-year-old man with a history of diabetes mellitus, benign prostatic hypertrophy, and hypertension had recently undergone percutaneous coronary intervention and was transferred to a hospital owing to a high fever and temporary loss of consciousness. The patient had been diagnosed with diabetes mellitus 8 months prior to the hospital admission with markedly elevated blood glucose and hemoglobin A1c levels (12.4 %). After the initiation of intensive insulin therapy, the patient’s serum glucose level was well controlled. The patient had undergone transurethral resection of the prostate 9 years earlier for treatment of urinary retention secondary to benign prostatic hypertrophy. However, urinary retention persisted, and the patient’s symptoms had been managed by an indwelling urinary catheter at home for 6 months. Ten days prior to the onset of fever, he had begun intermittent urethral self-catheterization.
The patient’s vital signs on admission were relatively stable. Although focal neurological symptoms were absent, magnetic resonance imaging of the head showed multiple acute emboli in the left parietal and posterior lobes. Blood and urine culture detected antimicrobial-susceptible P. aeruginosa, and treatment of ceftazidime (4 g per day) was initiated. Because of his sustained fever, blood cultures were redrawn on day 7, and they were positive for ceftazidime-resistant P. aeruginosa. Antibiotic therapy was changed to levofloxacin (500 mg per day) and continued for 2 weeks. During the hospitalization, transthoracic echocardiography (TTE) was performed twice (on day 1 and day 4), but no remarkable findings were observed. The patient’s symptoms resolved with antibiotic treatment, and he was discharged.
Three days after discharge, the high fever remerged, and the patient was readmitted. Physical examination did not show any abnormalities, but laboratory results showed elevated levels of white blood cells (9300/μL) and serum protein (12.5 mg/dL). Blood culture again detected P. aeruginosa, and magnetic resonance imaging of the head showed newly formed, multiple emboli accompanying micro-hemorrhages at the cerebral cortex and cerebellum bilaterally. IE was suspected, but TTE performed on the day of readmission did not reveal any structural abnormalities. Three days later, however, transesophageal echocardiography (TEE) revealed a movable, hypoechoic lesion at the aortic valve, along with new-onset severe aortic regurgitation (Fig. 1a). A patent foramen ovale (PFO) was also discovered (Fig. 1b). The patient was transferred to our hospital for emergency surgical treatment.
On arrival, a pan-diastolic murmur was auscultated, but there was no apparent peripheral embolic finding. Full body computed tomography did not reveal any other infectious foci. P. aeruginosa was repeatedly identified in blood cultures, and the antimicrobial susceptibility testing of the pathogen revealed the following minimum inhibitory concentrations: piperacillin, ≥128 μg/mL; ceftazidime, ≥32 μg/mL; cefepime, 16 μg/mL; aztreonam, ≥32 μg/mL; imipenem/cilastatin, 1 μg/mL; meropenem, ≤0.5 μg/mL; gentamicin, 4 μg/mL; tobramycin, ≤1 μg/mL; amikacin, 8 μg/mL; ciprofloxacin, ≤0.25 μg/mL; and levofloxacin, ≤0.5 μg/mL. An emergency operation for aortic valve replacement and PFO closure was performed, and a combination therapy of high-dose meropenem (6 g divided into 3 doses per day) and a single daily dose of tobramycin (300 mg per day, approximately 3.5 mg/kg/day) was initiated perioperatively. The post-operative clinical course was uneventful, and the patient completed a 6-week course of the combination antibiotic therapy. The dose of tobramycin was adjusted to target trough levels of 1 to 2 μg/mL, and the patient did not develop renal dysfunction during the treatment. The patient recovered well without recurrence after 1 year.

Discussion

P. aeruginosa endocarditis is a clinically rare condition. In an international study including 61 hospitals in 28 countries, the pathogen accounted for only 0.4 % (11/2761 cases) of all cases of IE [10]. Compared to right-sided disease, the left-sided P. aeruginosa endocarditis progresses rapidly with varied complications and serious outcomes [10]. According to a recent literature review summarizing 40 cases of the left-sided P. aeruginosa endocarditis in non-IVD abusers, the overall mortality was about 64 % (23/36 cases) [11]. However, most of the cases were reported more than 10 years previously, and current incidence and clinical features of this rare but fatal infection are uncertain.
For better comprehension of the left-sided P. aeruginosa endocarditis, we performed a review of literature published in the last decade (2005 to June 2015) in the MEDLINE database. Due to its low incidence, previous reports referring to HCA-IE did not particularly focus on this pathogen [25]. To the best of our knowledge, this is the first attempt to categorize such cases by their clinical backgrounds. A summary of 26 cases identified in the review (15 reports), including the presented case, is shown in Table 1 [1125].
Table 1
A summary of cases of left-sided infective endocarditis caused by Pseudomonas aeruginosa reported during the last decade (2005–2015)
No. [ref]
Year
Age/Sex
IVD
Underlying disease or intervention
Suspected source
Infected valves
Size and lesion
Complications
Treatment
Antibiotics
Outcome
Community-acquired IE
 1 [12]
2009
49/M
Yes
CKD
IVD
Prosthetic mitral/aortic
10 mm/5 mm
Unknown
Surgical
BL + AG
Survival
 2 [13]
2013
41/M
No
None
Unknown
Native mitral
20 mm
n.d.
Surgical
BL + AG
Survival
 3 [14]
2013
85/F
No
HT, DM
Unknown
Native mitral
4–8 mm
AVB
Medical
BL + AG
Death
Non-nosocomial healthcare-associated IE (NNHCA-IE)
 4 [15]
2005
56/F
No
DM
Unknown
Native mitral
17 mm
Meningitis
Medical
BL + AG
Survival
 5 [16]
2008
66/M
No
Cardiac surgery (AVR)
Unknown
Prosthetic mitral
11 × 12 mm
Sub-endocardial abscess
Surgical
BL
Death
 6 [11]
2011
71/M
No
Cardiac surgery (CABG), CAD,
Urinary tract (cystoscopy)
Native mitral
6 × 10 mm
Cerebral embolism
Surgical
CPM + FQ
Survival
 7 [11]
2011
65/M
No
Cardiac surgery (AD), DM
Infected toe
Prosthetic aortic
n.d.
Aortic root graft abscess
Surgical
BL + AG
Survival
 8 [11]
2011
45/M
No
Cardiac surgery (AVR, MVR, TAP), HD
Cardiac surgery
Prosthetic mitral
n.d.
n.d.
Medical
n.d.
Death
 9 [11]
2011
61/M
No
Cardiac surgery (e.g. AVR)
Cardiac surgery
Prosthetic aortic
n.d.
n.d.
Surgical
BL + AG
Death
 10 [17]
2012
63/M
No
DM, CHF, Implanted pacemaker, CKD
Unknown
Native mitral
5 mm
Aortic root abscess
Surgical
BL + AG
Death
 11 [18]
2012
73/M
No
MM, HT, DM, Af, chemotherapy
Infection of the lower limb
Native mitral
10 mm
n.d.
Medical
BL + FQ
Death
 12 [19]
2012
49/F
No
DM, CAD, CKD (HD), HT
Dialysis catheter
Native aortic
20 mm
n.d.
Medical
BL + AG
Survival
 13a
2015
66/M
No
DM, BPH, HT, CAD
Urinary tract
Native aortic
6 × 12 mm
Cerebral infarction
Surgical
CPM + AG
Survival
Nosocomial healthcare-associated IE (NHCA-IE)
 14 [20]
2008
45/F
No
Severe burn
Burn injury
Native aortic
n.d.
None
Medical
n.d.
Death
 15 [20]
2008
47/F
No
Severe burn
Burn injury
Native mitral
3 × 10 mm
Cerebral and renal embolism
Medical
n.d.
Death
 16 [20]
2008
31/M
No
Severe burn
Burn injury
Native mitral
3 × 5 mm
Cerebral embolism
Medical
n.d.
Death
 17 [21]
2009
69/M
No
Cardiac surgery (AVR)
Unknown
Prosthetic aortic
n.d.
Unknown
Surgical
FQ + AG
Survival
 18 [22]
2012
35/M
No
Renal transplantation
Surgery
Native aortic
6 × 13 mm
Splenic infarction
Medical
CPM + FQ
Survival
 19 [23]
2014
83/M
No
HD, CHF, Malignancy
Unknown
Prosthetic aortic
8 mm
Heart failure
Medical
CPM + COL
Death
 20 [23]
2014
55/M
No
Immunosuppressive therapy
Unknown
Native aortic
14 mm
Splenic infarction
Surgical
CPM + COL
Death
 21 [24]
2014
60/M
No
Myocardial infarction
Unknown
Native mitral
n.d.
Splenomegaly
Surgical
BL + AG
Survival
Uncertain cases
 22 [25]
2009
Unknown
Yes
Unknown
IVD
Prosthetic aortic
3 mm
Yes
Medical
BL + AG
Survival
 23 [25]
2009
Unknown
Yes
Unknown
IVD
Native mitral
4 mm
Yes
Medical
BL + AG
Survival
 24 [25]
2009
Unknown
Yes
Unknown
IVD
Native aortic
6 mm
Yes
Surgical
BL + AG
Survival
 25 [25]
2009
Unknown
Yes
Unknown
IVD
Prosthetic mitral
10 mm
Yes
Surgical
BL + AG
Survival
 26 [25]
2009
Unknown
Yes
Unknown
IVD
Native aortic
15 mm
Yes
Medical
BL + FQ
Death
AD aortic dissection, AF atrial fibrillation, AG aminoglycoside, AVB atrioventricular block, AVR aortic valve replacement, BL anti-pseudomonal beta-lactam, BPH benign prostatic hypertrophy, CABG coronary artery bypass grafting, CAD coronary artery disease, CHF chronic heart failure, CKD chronic kidney disease, COL colistin, CPM carbapenem, DM diabetes mellitus, FQ fluoroquinolone, HT hypertension, IE infective endocarditis, IVD intravenous drug use, MM multiple myeloma, MVR mitral valve replacement, SSS sick sinus syndrome, TAP tricuspid annuloplasty, n.d. not described
Non-nosocomial healthcare-associated cases are those that occurred in outpatients who had received medical care prior to the onset of infection
aCase No. 13 is the present case
There were 3 cases of community-acquired IE, 10 cases of NNHCA-IE, and 8 cases of nosocomial healthcare-associated IE (NHCA-IE). Five cases were inconclusive for their onset. Most cases were related to previous history of medical intervention. Involvements of the native valves were common (65.4 %, 17/26 cases), and systemic and cardiac complications occurred in approximately one-third (8/26 cases) and one-fifth (5/25 cases) of the cases, respectively. The mortality rate among patients with NNHCA-IE (50 %, 5/10 cases) was almost as high as that among patients with NHCA-IE (62.5 %, 5/8 cases). For outpatients, we generally do not suspect P. aeruginosa as a potential pathogen for IE, and thus, anti-pseudomonal agents are not empirically prescribed. We stress the importance of identifying the causative pathogen(s) in every cases of IE, especially in cases with a recent history of medical intervention.
The primary pathogen entry was undetermined in nearly half of the cases. Our patient repeatedly underwent urinary tract manipulations, and P. aeruginosa was noted in his urine sample. In addition, the urinary tract is reported to be a major site of pathogen entry in native valve endocarditis [26]. Moreover, it is known that genitourinary instrumentation accounts for the third most common etiology of HCA-IE, following vascular and digestive origination [2]. Thus, we suspect the damaged urethral mucosa was the pathogen entry site in the presented case. A similar case was also described in a recent NNHCA-IE case [11].
Compared to IVD abusers, who primarily develop right-sided infection, patients without a history of IVD abuse are prone to left-sided infection. A recent report demonstrated that 63 % (17/27 cases) of patients diagnosed with P. aeruginosa endocarditis without a history of IVD abuse developed left-sided heart infections [9]. Our review also revealed IVD abuse was less frequently associated with the left-sided P. aeruginosa endocarditis (23 %, 6/26 cases). This may be explained by the fact that a high-velocity blood jet stream damages the endocardium, and thus, the left side of the heart is more vulnerable to infection. Although the clinical significance is unknown, the presence of PFO may have been partially responsible for the left-sided involvement in this case.
Optimal treatment for the left-sided P. aeruginosa endocarditis has yet to be determined. Effectiveness of combination therapy with carbapenem and aminoglycosides for the infection has been reported [27], and therefore, we treated our patient with meropenem and tobramycin. Of the 26 cases reviewed, combination antibiotic therapy was prescribed in 21 cases (81 %). Monotherapy with ceftazidime was given in 1 case, but the patient died eventually [16]. Four cases did not mention antibiotic treatment. Among 14 successful cases, 5 patients underwent medical treatment alone, and 4 of them were treated with a combination of anti-pseudomonal beta-lactams and aminoglycosides. Of 9 successful cases with surgical treatment, the similar combined treatment was given in 6 cases. Although the effectiveness of antimicrobial combination therapy remains controversial, it may be preferable when the potential emergence of drug resistant strains during treatment is considered [28], as seen in our case. Thus, we consider that anti-pseudomonal beta-lactams or carbapenems combined with aminoglycosides can be a choice for cases of left-sided P. aeruginosa endocarditis.
The need for surgical intervention in the treatment for left-sided P. aeruginosa endocarditis should be carefully considered, as recent literature reports that the disease can be successfully treated medically [25, 27]. However, the results of our review show that the mortality rate in patients receiving medical treatment alone (62 %, 8/13 cases) was twice as high as that in patients receiving surgical treatment (31 %, 4/13 cases). The patients were not randomized, and critically ill patients or patients who had severe concomitant diseases tended to be treated by a medical approach alone. Thus, it is actually difficult to compare the survival rates of patients with medical or surgical treatment. However, medical treatment alone may be insufficient for left-sided P. aeruginosa endocarditis in some cases. A prospective, randomized study is warranted to elucidate the appropriate treatment strategy for this type of infection.

Conclusions

In conclusion, we described a rare case of left-sided NNHCA-IE caused by P. aeruginosa. The repeated manipulation of the urethra by intermittent self-catheterization was suspected as the cause of the infection. A literature review of cases of left-sided P. aeruginosa endocarditis revealed that non-nosocomial cases accounted for nearly half of the cases, and resulted in fatal outcomes as often as that noted in nosocomial cases. Optimal treatment is undetermined, but combination therapy with anti-pseudomonal beta-lactams or carbapenems and aminoglycosides would be preferable, according to the results of our review. Surgical indication for the disease should be carefully determined in every case.

Abbreviations

CA-IE, community-acquired IE; HCA-IE, healthcare-associated IE; IE, infective endocarditis; IVD, intravenous drug; NHCA-IE, nosocomial healthcare-associated IE; NNHCA-IE, non-nosocomial healthcare-associated IE; PFO, patent foramen ovale; TEE, transesophageal echocardiography; TTE, transthoracic echocardiography.

Acknowledgements

We would like to thank all medical staff who cared for the patient.

Funding

None to report.

Availability of data and materials

None to describe.

Authors’ contributions

HH mainly collected data and drafted the manuscript. TT and KT managed the patient at the clinical site and gave advice in drafting. HY, NY, YA, and KT participated in interpretation and discussion. KT finally approved the article. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.
Involvement of the ethical committee was not considered necessary, since this case report was not classified as a research study.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Literatur
1.
Zurück zum Zitat Fernandez-Hidalgo N, Almirante B, Tornos P, Pigrau C, Sambola A, Igual A, et al. Contemporary epidemiology and prognosis of health care-associated infective endocarditis. Clin Infect Dis. 2008;47:1287–97.CrossRefPubMed Fernandez-Hidalgo N, Almirante B, Tornos P, Pigrau C, Sambola A, Igual A, et al. Contemporary epidemiology and prognosis of health care-associated infective endocarditis. Clin Infect Dis. 2008;47:1287–97.CrossRefPubMed
2.
Zurück zum Zitat Lomas JM, Martinez-Marcos FJ, Plata A, Ivanova R, Galvez J, Ruiz J, et al. Healthcare-associated infective endocarditis: an undesirable effect of healthcare universalization. Clin Microbiol Infect. 2010;16:1683–90.CrossRefPubMed Lomas JM, Martinez-Marcos FJ, Plata A, Ivanova R, Galvez J, Ruiz J, et al. Healthcare-associated infective endocarditis: an undesirable effect of healthcare universalization. Clin Microbiol Infect. 2010;16:1683–90.CrossRefPubMed
3.
Zurück zum Zitat Benito N, Miro JM, de Lazzari E, Cabell CH, del Rio A, Altclas J, et al. Health care-associated native valve endocarditis: importance of non-nosocomial acquisition. Ann Intern Med. 2009;150:586–94.CrossRefPubMedPubMedCentral Benito N, Miro JM, de Lazzari E, Cabell CH, del Rio A, Altclas J, et al. Health care-associated native valve endocarditis: importance of non-nosocomial acquisition. Ann Intern Med. 2009;150:586–94.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Wu KS, Lee SS, Tsai HC, Wann SR, Chen JK, Sy CL, et al. Non-nosocomial healthcare-associated infective endocarditis in Taiwan: an underrecognized disease with poor outcome. BMC Infect Dis. 2011;11:221.CrossRefPubMedPubMedCentral Wu KS, Lee SS, Tsai HC, Wann SR, Chen JK, Sy CL, et al. Non-nosocomial healthcare-associated infective endocarditis in Taiwan: an underrecognized disease with poor outcome. BMC Infect Dis. 2011;11:221.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Yang F, Zhang B, Yu J, Shao L, Zhou P, Zhu L, et al. Epidemiology and the prognosis of healthcare-associated infective endocarditis in China: the significance of non-nosocomial acquisition. Emerg Microbes Infect. 2015;4, e38.CrossRefPubMedPubMedCentral Yang F, Zhang B, Yu J, Shao L, Zhou P, Zhu L, et al. Epidemiology and the prognosis of healthcare-associated infective endocarditis in China: the significance of non-nosocomial acquisition. Emerg Microbes Infect. 2015;4, e38.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Murdoch DR, Corey GR, Hoen B, Miro JM, Fowler Jr VG, Bayer AS, et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med. 2009;169:463–73.CrossRefPubMedPubMedCentral Murdoch DR, Corey GR, Hoen B, Miro JM, Fowler Jr VG, Bayer AS, et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med. 2009;169:463–73.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Reyes MP, Palutke WA, Wylin RF. Pseudomonas endocarditis in the Detroit Medical Center. 1969–1972. Medicine (Baltimore). 1973;52:173–94.CrossRef Reyes MP, Palutke WA, Wylin RF. Pseudomonas endocarditis in the Detroit Medical Center. 1969–1972. Medicine (Baltimore). 1973;52:173–94.CrossRef
8.
Zurück zum Zitat Cohen PS, Maguire JH, Weinstein L. Infective endocarditis caused by gram-negative bacteria: a review of the literature, 1945–1977. Prog Cardiovasc Dis. 1980;22:205–42.CrossRefPubMed Cohen PS, Maguire JH, Weinstein L. Infective endocarditis caused by gram-negative bacteria: a review of the literature, 1945–1977. Prog Cardiovasc Dis. 1980;22:205–42.CrossRefPubMed
9.
Zurück zum Zitat Lin TI, Huang YF, Liu PY, Chou CA, Chen YS, Chen YY, et al. Pseudomonas aeruginosa infective endocarditis in patients who do not use intravenous drugs: analysis of risk factors and treatment outcomes. J Microbiol Immunol Infect. 2014. Lin TI, Huang YF, Liu PY, Chou CA, Chen YS, Chen YY, et al. Pseudomonas aeruginosa infective endocarditis in patients who do not use intravenous drugs: analysis of risk factors and treatment outcomes. J Microbiol Immunol Infect. 2014.
10.
Zurück zum Zitat Morpeth S, Murdoch D, Cabell CH, Karchmer AW, Pappas P, Levine D, et al. Non-HACEK gram-negative bacillus endocarditis. Ann Intern Med. 2007;147:829–35.CrossRefPubMed Morpeth S, Murdoch D, Cabell CH, Karchmer AW, Pappas P, Levine D, et al. Non-HACEK gram-negative bacillus endocarditis. Ann Intern Med. 2007;147:829–35.CrossRefPubMed
11.
Zurück zum Zitat Dawson NL, Brumble LM, Pritt BS, Yao JD, Echols JD, Alvarez S. Left-sided Pseudomonas aeruginosa endocarditis in patients without injection drug use. Medicine (Baltimore). 2011;90:250–5.CrossRef Dawson NL, Brumble LM, Pritt BS, Yao JD, Echols JD, Alvarez S. Left-sided Pseudomonas aeruginosa endocarditis in patients without injection drug use. Medicine (Baltimore). 2011;90:250–5.CrossRef
12.
Zurück zum Zitat Daas H, Abuhmaid F, Zervos M. Successful treatment of Candida parapsilosis and Pseudomonas aeruginosa infection using medical and surgical management in an injecting drug user with mitral and aortic valve endocarditis: a case report. J Med Case Rep. 2009;3:6598.CrossRefPubMedPubMedCentral Daas H, Abuhmaid F, Zervos M. Successful treatment of Candida parapsilosis and Pseudomonas aeruginosa infection using medical and surgical management in an injecting drug user with mitral and aortic valve endocarditis: a case report. J Med Case Rep. 2009;3:6598.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Yilmaz M, Sunar H, Mert A. Community-acquired left-sided Pseudomonas aeruginosa endocarditis in a patient without intravenous drug use. Infection. 2013;41:243–5.CrossRefPubMed Yilmaz M, Sunar H, Mert A. Community-acquired left-sided Pseudomonas aeruginosa endocarditis in a patient without intravenous drug use. Infection. 2013;41:243–5.CrossRefPubMed
14.
Zurück zum Zitat Setoguchi M, Iwasawa E, Hashimoto Y, Isobe M. A patient with infective endocarditis caused by community-acquired Pseudomonas aeruginosa infection. Intern Med. 2013;52:1259–62.CrossRefPubMed Setoguchi M, Iwasawa E, Hashimoto Y, Isobe M. A patient with infective endocarditis caused by community-acquired Pseudomonas aeruginosa infection. Intern Med. 2013;52:1259–62.CrossRefPubMed
15.
Zurück zum Zitat Venkatesan A, Spalding C, Speedie A, Sinha G, Rumbaugh JA. Pseudomonas aeruginosa infective endocarditis presenting as bacterial meningitis. J Infect. 2005;51:e199–202.CrossRefPubMed Venkatesan A, Spalding C, Speedie A, Sinha G, Rumbaugh JA. Pseudomonas aeruginosa infective endocarditis presenting as bacterial meningitis. J Infect. 2005;51:e199–202.CrossRefPubMed
16.
Zurück zum Zitat Reinsch N, Plicht B, Lind A, Janosi RA, Buck T, Kamler M, et al. Recurrent infective endocarditis with uncommon Gram-negative Pasteurella multocida and Pseudomonas aeruginosa: a case report. J Heart Valve Dis. 2008;17:710–3.PubMed Reinsch N, Plicht B, Lind A, Janosi RA, Buck T, Kamler M, et al. Recurrent infective endocarditis with uncommon Gram-negative Pasteurella multocida and Pseudomonas aeruginosa: a case report. J Heart Valve Dis. 2008;17:710–3.PubMed
17.
Zurück zum Zitat Aggarwal A, Ritter N, Reddy L, Lingutla D, Nasar F, El-Daher N, et al. Recurrent Pseudomonas aortic root abscess complicating mitral valve endocarditis. Heart Lung. 2012;41:181–3.CrossRefPubMed Aggarwal A, Ritter N, Reddy L, Lingutla D, Nasar F, El-Daher N, et al. Recurrent Pseudomonas aortic root abscess complicating mitral valve endocarditis. Heart Lung. 2012;41:181–3.CrossRefPubMed
18.
Zurück zum Zitat Todaro J, Bollmann PW, Nussbacher A, Camargo LF, Santos BF, Alvarenga D, et al. Multiple myeloma complicated with pseudomonas endocarditis. Einstein (Sao Paulo). 2012;10:498–501.CrossRef Todaro J, Bollmann PW, Nussbacher A, Camargo LF, Santos BF, Alvarenga D, et al. Multiple myeloma complicated with pseudomonas endocarditis. Einstein (Sao Paulo). 2012;10:498–501.CrossRef
19.
Zurück zum Zitat Hassan KS, Al-Riyami D. Infective endocarditis of the aortic valve caused by Pseudomonas aeruginosa and treated medically in a patient on haemodialysis. Sultan Qaboos Univ Med J. 2012;12:120–3.CrossRefPubMedPubMedCentral Hassan KS, Al-Riyami D. Infective endocarditis of the aortic valve caused by Pseudomonas aeruginosa and treated medically in a patient on haemodialysis. Sultan Qaboos Univ Med J. 2012;12:120–3.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Regules JA, Glasser JS, Wolf SE, Hospenthal DR, Murray CK. Endocarditis in burn patients: clinical and diagnostic considerations. Burns. 2008;34:610–6.CrossRefPubMed Regules JA, Glasser JS, Wolf SE, Hospenthal DR, Murray CK. Endocarditis in burn patients: clinical and diagnostic considerations. Burns. 2008;34:610–6.CrossRefPubMed
21.
Zurück zum Zitat Kato Y, Ohashi H, Tsutsumi Y, Murakami T, Takahashi Y. Prosthetic valve endocarditis caused by metallo-beta-lactamase-producing Pseudomonas aeruginosa. J Card Surg. 2009;24:347–9.CrossRefPubMed Kato Y, Ohashi H, Tsutsumi Y, Murakami T, Takahashi Y. Prosthetic valve endocarditis caused by metallo-beta-lactamase-producing Pseudomonas aeruginosa. J Card Surg. 2009;24:347–9.CrossRefPubMed
22.
Zurück zum Zitat Nasim A, Baqi S, Akhtar SF. Pseudomonas aeruginosa endocarditis in renal transplant recipients. Transpl Infect Dis. 2012;14:180–3.CrossRefPubMed Nasim A, Baqi S, Akhtar SF. Pseudomonas aeruginosa endocarditis in renal transplant recipients. Transpl Infect Dis. 2012;14:180–3.CrossRefPubMed
23.
Zurück zum Zitat Durante-Mangoni E, Andini R, Agrusta F, Iossa D, Mattucci I, Bernardo M, et al. Infective endocarditis due to multidrug resistant gram-negative bacilli: single centre experience over 5 years. Eur J Intern Med. 2014;25:657–61.CrossRefPubMed Durante-Mangoni E, Andini R, Agrusta F, Iossa D, Mattucci I, Bernardo M, et al. Infective endocarditis due to multidrug resistant gram-negative bacilli: single centre experience over 5 years. Eur J Intern Med. 2014;25:657–61.CrossRefPubMed
24.
Zurück zum Zitat Polovina M, Potpara T, Milosevic I, Stepanovic J, Jovanovic M, Pavlovic M. Mitral valve endocarditis caused by Pseudomonas aeruginosa: a case report. J Infect Dev Ctries. 2014;8:676–9.CrossRefPubMed Polovina M, Potpara T, Milosevic I, Stepanovic J, Jovanovic M, Pavlovic M. Mitral valve endocarditis caused by Pseudomonas aeruginosa: a case report. J Infect Dev Ctries. 2014;8:676–9.CrossRefPubMed
25.
Zurück zum Zitat Reyes MP, Ali A, Mendes RE, Biedenbach DJ. Resurgence of Pseudomonas endocarditis in Detroit, 2006–2008. Medicine (Baltimore). 2009;88:294–301.CrossRef Reyes MP, Ali A, Mendes RE, Biedenbach DJ. Resurgence of Pseudomonas endocarditis in Detroit, 2006–2008. Medicine (Baltimore). 2009;88:294–301.CrossRef
26.
Zurück zum Zitat Meyers BR, Sherman E, Mendelson MH, Velasquez G, Srulevitch-Chin E, Hubbard M, et al. Bloodstream infections in the elderly. Am J Med. 1989;86:379–84.CrossRefPubMed Meyers BR, Sherman E, Mendelson MH, Velasquez G, Srulevitch-Chin E, Hubbard M, et al. Bloodstream infections in the elderly. Am J Med. 1989;86:379–84.CrossRefPubMed
27.
Zurück zum Zitat Gavin PJ, Suseno MT, Cook FV, Peterson LR, Thomson Jr RB. Left-sided endocarditis caused by Pseudomonas aeruginosa: successful treatment with meropenem and tobramycin. Diagn Microbiol Infect Dis. 2003;47:427–30.CrossRefPubMed Gavin PJ, Suseno MT, Cook FV, Peterson LR, Thomson Jr RB. Left-sided endocarditis caused by Pseudomonas aeruginosa: successful treatment with meropenem and tobramycin. Diagn Microbiol Infect Dis. 2003;47:427–30.CrossRefPubMed
28.
Zurück zum Zitat Fichtenbaum CJ, Smith MJ. Treatment of endocarditis due to Pseudomonas aeruginosa with imipenem. Clin Infect Dis. 1992;14:353–4.CrossRefPubMed Fichtenbaum CJ, Smith MJ. Treatment of endocarditis due to Pseudomonas aeruginosa with imipenem. Clin Infect Dis. 1992;14:353–4.CrossRefPubMed
Metadaten
Titel
Non-nosocomial healthcare-associated left-sided Pseudomonas aeruginosa endocarditis: a case report and literature review
verfasst von
Hideharu Hagiya
Takeshi Tanaka
Kohei Takimoto
Hisao Yoshida
Norihisa Yamamoto
Yukihiro Akeda
Kazunori Tomono
Publikationsdatum
01.12.2016
Verlag
BioMed Central
Erschienen in
BMC Infectious Diseases / Ausgabe 1/2016
Elektronische ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-016-1757-y

Weitere Artikel der Ausgabe 1/2016

BMC Infectious Diseases 1/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.